Intravascular ultrasound assessment of optimal stent area to prevent in‐stent restenosis after zotarolimus‐, everolimus‐, and sirolimus‐eluting stent implantation
- 19 July 2012
- journal article
- research article
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 83 (6), 873-878
- https://doi.org/10.1002/ccd.24560
Abstract
Objectives and background The impact of underexpansion and minimal stent area (MSA) criteria in the second generation drug-eluting stents (DES) has not been addressed yet. Methods Using intravascular ultrasound (IVUS), we assessed the optimal cut-off values of post-stenting MSA to prevent in-stent restenosis (ISR). Poststenting IVUS data and 9-month follow-up angiography were available in 912 patients with 990 lesions: 541 sirolimus-eluting stents (SES), 220 zotarolimus-eluting stents (ZES) and 229 everolimus-eluting stents (EES). Results For the prediction of angiographic ISR, the MSA of each DES was measured. The poststenting MSA was 6.4 ± 1.8 mm2 in SES, 6.2 ± 2.1 mm2 in ZES and 6.2 ± 2.1 mm2 in EES. At the 9-months follow-up, the incidence of angiographic ISR was similar between SES (3.3%) vs. ZES (4.5%) vs. EES. (4.4%), (P = 0.53). Multivariable logistic regression analysis identified the post-stenting MSA as the only independent predictor of angiographic ISR in ZES (Odds ratio 0.722, 95% confidence interval 0.581–0.897, P = 0.001) and in EES (Odds ratio 0.595, 95% confidence interval 0.392–0.904, P = 0.015). The best MSA cut-off value was 5.5 mm2 for the prediction of SES restenosis (sensitivity 72.2% and specificity 66.3%). For ZES, the optimal MSA predicting ISR was 5.3 mm2 (sensitivity 56.7% and specificity 61.8%). For EES, the MSA 2 predicted ISR (sensitivity 60.0% and specificity 60.0%). Conclusions As a preventable mechanism of ISR, smaller stent area predicted angiographic restenosis of the second generation DES as well as the first generation. The optimal cut-off values of post-stenting MSA for preventing restenosis were similar between ZES vs. EES vs. SES.Keywords
This publication has 15 references indexed in Scilit:
- Clinical Evaluation of the Resolute Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries: The RESOLUTE US Clinical TrialJournal of the American College of Cardiology, 2011
- Everolimus or paclitaxel stents in real life: go COMPARE.The Lancet, 2010
- Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trialThe Lancet, 2010
- Comparison of an Everolimus-Eluting Stent and a Paclitaxel-Eluting Stent in Patients With Coronary Artery DiseaseJAMA, 2008
- Intravascular ultrasound predictors of angiographic restenosis after sirolimus-eluting stent implantationEuropean Heart Journal, 2006
- Quantitative Assessment of Angiographic Restenosis After Sirolimus-Eluting Stent Implantation in Native Coronary ArteriesCirculation, 2004
- Impact of final stent dimensions on long-term results following sirolimus-eluting stent implantation: Serial intravascular ultrasound analysis from the sirius trialJournal of the American College of Cardiology, 2004
- Clinical, Angiographic, and Procedural Predictors of Angiographic Restenosis After Sirolimus-Eluting Stent Implantation in Complex PatientsCirculation, 2004
- Preliminary Observations Regarding Angiographic Pattern of Restenosis After Rapamycin-Eluting Stent ImplantationCell Metabolism, 2003
- Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty).Circulation, 1988